Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces Date and Time for Third Quarter 2026 Earnings and Conference Call7.10.2026 22:05:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / October 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q3 2026 earnings before the market opens on Thursday, November 5, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loa
Surmodics Launches IOL Cartridge Coating Automation Center in Horsham7.10.2026 21:30:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 7, 2026 / Surmodics, a provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the American Academy of Ophthalmology annual meeting in New Orleans the launch of its IOL Cartridge Coating Automation Center at its Horsham, Pennsylvania site just outside Philadelphia. "The delivery system for an intraocular lens (IOL) combines precision injection-molded parts with a specifically selected lubricious, biofriendly coating," said Chip Hance, CEO of Surmodics. "As IOL manufacturers increasingly seek automated assembly and modern biomaterial formulations, our Automation Center provides automated coating processes designed for efficient production throughout the product lifecycle." The center brings together advanced hydrophilic coating technology, decades of IOL cartridge application expertise, precision coatings processes and automation capabilities in a manufacturing platform developed
Nevada Court Lifts Restriction, Clearing EESystem to Share Recording of November 2024 Meeting7.10.2026 15:00:00 CEST | Press release
LAS VEGAS, NV / ACCESS Newswire / October 7, 2026 / On September 25, 2026, Judge Erika Mendoza of the Eighth Judicial District Court of Nevada, Clark County, entered a written order denying Jason Shurka's motion for a preliminary injunction and granting Michael Bertolacini's motion to dissolve a temporary restraining order that had barred public dissemination of a recording of a November 14, 2024 meeting. The ruling was issued in Case No. A-25-910216-B, Department XXVII, a matter brought by Energy Enhancement System LLC ("EESystem"), Michael Bertolacini and Dr. Sandra Rose Michael against Jason Shurka and other defendants. In its written order, the court stated that its earlier suggestion that Jason Shurka's consent was needed to share the recording was incorrect, and that the restriction was dissolved as of the September 2, 2026 hearing. According to the order, the meeting was recorded on a cellphone by Manny Shurka, Jason Shurka's father, and Jason Shurka produced that recording in t
Steelcase 2025 Impact Report Highlights Progress in Reducing Emissions and Strengthening Communities7.10.2026 15:00:00 CEST | Press release
GRAND RAPIDS, MI / ACCESS Newswire / October 7, 2026 / Steelcase, a global design and thought leader in the world of work, today released its 2025 Impact Report, "Our Work Toward Better Futures." Steelcase recorded reductions in scope 1 and 2 emissions by 33% from its 2019 baseline and activated 324 Better Futures Community partnerships across 38 locations. The report details how Steelcase members, customers and partners are helping communities thrive and moving the organization closer to net zero. "Our commitments to people and the planet help focus the choices we make, the partnerships we build and the value we create," said Megan Blazina, senior vice president, international, digital and strategy at Steelcase, who also leads sustainability and social impact. "The progress in this report reflects how we're turning those commitments into action." As Steelcase looks ahead as a new part of HNI Corporation, the companies' shared focus on the wellbeing of people and the planet provides a
PostSig Expands Enterprise Platform for Financial and Operational Control7.10.2026 15:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 7, 2026 / PostSig today introduced a significant expansion of its enterprise platform, giving Finance, Procurement, Market Data and Operations teams a shared foundation for managing commercial performance. The expansion follows PostSig being named Best Data Governance Solution in WatersTechnology's 2026 Inside Market Data & Inside Reference Data Awards and its first enterprise deployment with data consultancy CJC, which manages market data for a London multi-asset broker. Pricing schedules, service orders, product inventories and entitlements change over time. When teams manage those records separately, they may see individual values but cannot reliably determine which one applies, why it changed, or how the change should affect spend. "Commercial commitments do not stop at the document," said Hendrik Bartel, CEO and Co-Founder of PostSig. "They show up in products, pricing, invoices, entitlements, usage, and accountability. PostSig connect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom